Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-grazytracer PET/CT for Immunotherapy Response
NCT05000372Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2021
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Incidence of 68Ga-grazytracer-emergent Adverse Events at 3 years, Biodistribution of 68Ga-grazytracer at 3 years and 2 more. Started Sep 2021; status: completed.
Beyond the preview
Go deeper on NCT05000372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05000372.